



For immediate release – December 19, 2008

## **DIDIER PEOC'H NAMED GROUP DIRECTOR FOR RESEARCH AND DEVELOPMENT OF THE VÉTOQUINOL GROUP**

Lure (France), 19 December 2008 - Didier Peoc'h, 41 years old, received his PhD in Biomolecular Chemistry from the University of Technical Sciences at Montpellier. He has 15 years of experience in pharmaceutical and biotechnology development.

Following one year of fundamental research at the French Public Research Institute (CNRS), Mr. Peoc'h began his career in the pharmaceutical industry in the United States, in 1994, as a senior scientist in the medicinal chemistry department at ISIS Pharmaceuticals, a biopharmaceutical development company located in California. In 1997, he joined the French subsidiary of the Catalent group – one of the world's leading providers of advanced technologies to the pharmaceutical and biotechnology industries – as Director of Technology Transfer. In 2000 he was named Director of Research and Development of the French division, and in 2005 he moved to the parent company in New Jersey (USA) as Corporate Director of Innovation and New Technologies. He held that responsibility until returning to France to take the position of Group Director for Research and Development at Vétoquinol.

Commenting on the appointment, Etienne Frechin, Chairman of Vétoquinol, said, "I am delighted to welcome M. Peoc'h to Vétoquinol. He brings new perspectives and complementary skills to the group."

Upcoming events: 2008 Annual revenues (Thursday, 22 January 2009)

### **About Vétoquinol**

*Vétoquinol, which is celebrating its 75<sup>th</sup> anniversary in 2008, is an independent veterinary pharmaceutical laboratory serving both the companion animal and livestock markets. This family-owned group specialized in animal health is the 11<sup>th</sup> largest laboratory in the world, and nearly 80% of Vétoquinol's revenues come from outside France.*

*Vétoquinol engages in the research and development, production and marketing of medical and dietary products. Vétoquinol has positioned itself in the curative sector, and has developed expertise in three major therapeutic fields: anti-infectives, pain management and anti-inflammatories, and cardiology and nephrology.*

*The Group currently distributes its products in one hundred countries throughout Europe, North America and Asia, with subsidiaries in 22 different countries and a network of 110 distributor partners. The Company has more than 1,400 employees worldwide.*

**More information:** [www.vetoquinol.com](http://www.vetoquinol.com).

**OUR BUSINESS: ANIMALS. OUR ADVANTAGE: PEOPLE.**

For further information, contact

#### **VETOQUINOL**

Finance Department  
Pierre KONAREFF  
Tel: +33 (0)3 84 62 59 88  
[relations.investisseurs@vetoquinol.com](mailto:relations.investisseurs@vetoquinol.com)

#### **KEIMA COMMUNICATION**

Investor Relations  
Emmanuel DOVERGNE  
Tel: +33 (0)1 56 43 44 63  
[emmanuel.dovergne@keima.fr](mailto:emmanuel.dovergne@keima.fr)

#### Media Relations

Alix HÉRIARD DUBREUIL  
Tel: +33 (0)1 56 43 44 62  
[alix.heriard@keima.fr](mailto:alix.heriard@keima.fr)